Compare Matson Inc (MATX) vs Medpace Holdings Inc (MEDP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Matson Inc vs Medpace Holdings Inc — how do they compare? Matson Inc trades at $225.53 (market cap $6.81B), while Medpace Holdings Inc trades at $611.57 (market cap $16.82B). The key difference: Medpace Holdings Inc is far larger — about 2.5× Matson Inc's market cap, and Matson Inc pays a 0.67% dividend while Medpace Holdings Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Matson Inc for 23 Days and Medpace Holdings Inc for 14 Days on average.
| MATX | MEDP | |
|---|---|---|
Market Cap | $6.81B | $16.82B |
Volume | 255,080 | 223,093 |
Sector | Industrials | Health |
52-Week High | $238.60 | $630.19 |
52-Week Low | $88.05 | $393.42 |
Typical Hold Time | 23 Days | 14 Days |
Enterprise Value | $7.41B | $16.44B |
Dividend Yield | 0.67% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Matson (MATX) trades at $224.80, up 0.84% on the day, with a bullish technical signal from moving averages and a neutral stance from oscillators. The company reported strong Q2 2026 earnings of $4.27 per share, beating estimates, and raised its full-year outlook. Revenue growth is steady, with 2026 revenue projected at $3.5 billion and net profit at $464 million, supported by a robust net income margin of 13.41%.
The outlook for MATX is positive, driven by earnings beats, cost controls, and institutional accumulation. Key risks include exposure to freight demand cycles and competitive pressures. Wall Street consensus is bullish, with 8 of 12 analysts rating it a Buy and an implied 27.33% upside potential, though investors should monitor macroeconomic trends affecting transportation stocks.
Medpace (MEDP) trades at $617.47, up 2.19% with strong quarterly earnings beats and robust profitability metrics. The stock shows neutral technical signals with key resistance at $620, while fundamentals reveal impressive ROE of 162.15% and consistent revenue growth to $2.8B projected for 2026. Recent CEO stock sales and mixed institutional activity create balanced sentiment ahead of Q3 earnings announcement on October 21, 2026.
MEDP presents growth potential with analyst consensus target of $620.44 and strong historical execution, though elevated valuations (P/E 35.41) and insider selling warrant caution. The stock's upside depends on continued earnings delivery amid competitive medical services landscape.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Matson Inc
Matson, Inc. is an American shipping and logistics company primarily operating in the Pacific. The company provides ocean transportation services, including container, automobile, and general cargo, particularly between the U.S. West Coast, Hawaii, Alaska, and Guam. Matson also offers logistics services, including warehousing, less-than-container load (LCL) consolidation, and supply chain management, making it a critical service provider for businesses operating across the Pacific region.
Read more on MATX →About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →
